| Trial ID: | L4794 |
| Source ID: | NCT05232708
|
| Associated Drug: |
Semaglutide B, 1.34 Mg/Ml
|
| Title: |
A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Healthy Volunteers (Diabetes Mellitus, Type 2)
|
| Interventions: |
DRUG: Semaglutide B, 1.34 mg/mL|DRUG: Semaglutide D, 1.0 mg/mL|DRUG: Semaglutide D, 1.0 mg/mL|DRUG: Semaglutide B, 1.34 mg/mL
|
| Outcome Measures: |
Primary: AUC0-last,sema 0.5mg: Area under the semaglutide concentration-time curve from time 0 until last quantifiable measurement after single dose of s.c. semaglutide 0.5 mg, Measured in h\*nmol/L, 0-840 hours after a single dose of s.c. semaglutide 0.5 mg|Cmax,sema,0.5mg: maximum observed semaglutide concentration-time after single dose of s.c. semaglutide 0.5 mg administration, Measured in nmol/L, 0-840 hours after a single dose of s.c. semaglutide 0.5 mg |
|
| Sponsor/Collaborators: |
Sponsor: Novo Nordisk A/S
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2022-01-19
|
| Completion Date: |
2022-08-30
|
| Results First Posted: |
|
| Last Update Posted: |
2024-01-26
|
| Locations: |
Parexel CPRU, Level 7, Harrow, Middlesex, HA1 3UJ, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT05232708
|
